Curevo secures $110M series B to advance Amezosvatein Shingles Vaccine

Seattle, WA, March 17, 2025 (Globe Newswire) -- Curevo Vaccine, a clinical-stage biotechnology company specializing in varicella zoster virus vaccines, has raised $110 million in a Series B funding round to support the development of amezosvatein, its shingles vaccine candidate. The financing was led by Medicxi, alongside new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures, with continued support from existing investors such as RA Capital Management and GC Biopharma. CEO George Simeon announced that the funding will extend the company’s Phase 2 study to 640 additional participants, focusing on adults over 70, to refine dose selection before advancing to Phase 3 trials. Additionally, Moncef Slaoui, former Chair of GSK’s vaccine division and Chief Scientific Advisor to Operation Warp Speed, will join Curevo as Board Chair.

Read full article here.